Acushnet has retired 22.2% of its shares since 2018, from 75,029,111 to 58,405,044.
At $80.25 a share, a market value of $4.7B. P/E 21.3, trailing twelve months to June 2026.
| Fiscal year | Date | Shares outstanding | Filing | |
|---|---|---|---|---|
| 2016 | 2017-03-24 | 74,451,977 | 10-K | |
| 2017 | 2018-03-02 | 74,744,536 | 10-K | |
| 2018 | 2019-02-22 | 75,029,111 | 10-K | |
| 2019 | 2020-02-21 | 74,383,716 | 10-K/A | |
| 2020 | 2021-02-19 | 74,294,813 | 10-K | |
| 2021 | 2022-02-25 | 72,379,964 | 10-K | |
| 2022 | 2023-02-24 | 66,945,802 | 10-K | |
| 2023 | 2024-02-23 | 63,494,735 | 10-K | |
| 2024 | 2025-02-21 | 59,928,969 | 10-K | |
| 2025 | 2026-02-20 | 58,560,358 | 10-K |
Source: all 10-K filings of Acushnet on EDGAR. Download this series as CSV. Licence CC BY 4.0, credit Buyback Radar.
The story
Every Monday we write about one of these companies.
Read the full storyCash spent comes from the cash flow statement. Shares outstanding fell by less than the company bought, because part of every buyback only replaces shares handed to employees. Today’s price is $80.25.
Loading the chart from TradingView…
All-time chart by TradingView. Open it on TradingView →
Only enough to stand still. The share count is roughly flat over the last twelve months, at 58,405,044 as of July 31, 2026. Over five years the share count is down 20.7%.
Net of every new share it issued, Acushnet has 16.6 million fewer shares than at its 2018 peak. That is 22.2% of the company. Since fiscal 2019 alone it bought back about 19.2 million shares, while the count fell by 16.0 million. The difference went to employees and other new shares.
58,405,044 shares, as of July 31, 2026, from the cover page of its latest 10-Q. At the 2018 peak it had 75,029,111.
Each share is a bigger slice of the company. Someone who held Acushnet stock in 2018 owns 1.3 times as much of the business today without buying another share. Whether that was a good use of cash depends on the price paid.
Acushnet ranks No. 350 of 467 companies on Buyback Radar by share of the company retired since its peak. Close to it on the list: CTS (22.3%), General Electric (22.2%), Genuine Parts (22.0%), Halozyme Therapeutics (21.7%).
Every answer is computed from Acushnet's own SEC filings and rebuilt every Monday. Latest count: 10-Q on EDGAR.
Free. Your email goes to Substack, which runs the newsletter. Privacy